Russia views risk-sharing mechanism for public procurement of expensive innovative drugs

The Russian government is considering introducing a risk-sharing mechanism for public procurement of expensive innovative drugs.

If amendments to the law are adopted, pharmaceutical companies will be able to receive payment for their drugs only if the condition of the patient improved as a result drug intake, reports The Pharma Letter’s local correspondent.

As follows from the explanatory note to the draft amendments to Federal Law-44, it is becoming more difficult for the government to provide patients with increasingly expensive medicines. Therefore, alternative schemes that ensure the maximum effectiveness of budget expenditures, eliminating or minimizing unproductive spending are expected to be adopted.